论文部分内容阅读
目的对比分析优泌乐25和优泌林70/30治疗2型糖尿病的疗效与安全性。方法 100例口服药无效的2型糖尿病患者,按照治疗方法的不同,将其随机分为观察组和对照组,每组50例。对照组给予优泌林70/30治疗,观察组给予优泌乐25治疗,比较两组患者治疗前后空腹血糖、餐后2 h血糖、糖化血红蛋白(HbA1c)值以及轻微低血糖、严重低血糖发生次数。结果两组患者治疗后较治疗前空腹血糖、餐后2 h血糖、HbA1c值均有显著下降(P<0.05);观察组治疗后餐后2 h血糖、HbA1c值显著优于对照组(P<0.05);治疗后观察组轻微低血糖、严重低血糖发生次数显著少于对照组(P<0.05)。结论优泌乐25较优泌林70/30治疗2型糖尿病的疗效与安全性更加显著,值得临床推广应用。
Objective To compare and analyze the efficacy and safety of Uehara 25 and Uehara 70/30 in the treatment of type 2 diabetes mellitus. Methods One hundred patients with type 2 diabetes who were ineffective oral medication were randomly divided into observation group and control group with 50 cases in each group according to the different treatment methods. The control group was treated with Euclidean 70/30, and the observation group was treated with Uehara Le 25. The fasting blood glucose, postprandial 2-hour postprandial blood glucose, HbA1c, mild hypoglycemia and severe hypoglycemia were compared between two groups frequency. Results After treatment, the levels of fasting blood glucose, postprandial 2-h blood glucose and HbA1c in both groups were significantly decreased (P <0.05). After 2-hour postprandial postprandial blood glucose and HbA1c values in the two groups were significantly better than those in the control group (P < 0.05). After treatment, the incidence of mild hypoglycemia and severe hypoglycemia in observation group was significantly less than that in control group (P <0.05). Conclusions Euthyrox 25 is the more effective and safe treatment for type 2 diabetes mellitus than the more effective Elulin 70/30, which is worthy of clinical application.